Anoctamin pharmacology

• Published in: Cell calcium (Edinburgh) 2024-07, Vol.121, p.102905-102905, Article 102905
• Main Authors: Genovese, Michele, Galietta, Luis J.V.
• Format: Article
• Language: English
• Subjects: Animals; Anoctamin-1 - antagonists & inhibitors; Anoctamin-1 - metabolism; Anoctamins - metabolism; Calcium signaling; Channel inhibitor; Channel potentiator; Chloride channel; Chloride Channels - antagonists & inhibitors; Chloride Channels - metabolism; Drug screening; Humans; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - metabolism; Phospholipid Transfer Proteins - antagonists & inhibitors; Phospholipid Transfer Proteins - metabolism
• ISSN: 0143-4160; 1532-1991
• DOI: 10.1016/j.ceca.2024.102905

TMEM16 proteins, also known as anoctamins, are a family of ten membrane proteins with various tissue expression and subcellular localization. TMEM16A (anoctamin 1) is a plasma membrane protein that acts as a calcium-activated chloride channel. It is expressed in many types of epithelial cells, smooth muscle cells and some neurons. In airway epithelial cells, TMEM16A expression is particularly enhanced by inflammatory stimuli that also promote goblet cell metaplasia and mucus hypersecretion. Therefore, pharmacological modulation of TMEM16A could be beneficial to improve mucociliary clearance in chronic obstructive respiratory diseases. However, the correct approach to modulate TMEM16A activity (activation or inhibition) is still debated. Pharmacological inhibitors of TMEM16A could also be useful as anti-hypertensive agents given the TMEM16A role in smooth muscle contraction. In contrast to TMEM16A, TMEM16F (anoctamin 6) behaves as a calcium-activated phospholipid scramblase, responsible for the externalization of phosphatidylserine on cell surface. Inhibitors of TMEM16F could be useful as anti-coagulants and anti-viral agents. The role of other anoctamins as therapeutic targets is still unclear since their physiological role is still to be defined. [Display omitted]